aTyr Pharma Inc. (LIFE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.85-0.20 (-6.56%)
At close: 4:00 PM EDT
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close3.05
Bid2.85 x 1100
Ask2.90 x 6800
Day's Range2.83 - 3.05
52wk Range2.48 - 13.26
1y Target EstN/A
Market Cap67.6M
P/E Ratio (ttm)-1.14
Avg Vol (3m)196,452
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • 24/7 Wall St.yesterday

    aTyr Receives FDA Fast Track Designation

    aTyr Pharma watched its shares climb early on Monday after the company announced that its product candidate Resolaris was granted Fast Track designation by the FDA.

  • PR Newswireyesterday

    aTyr Pharma Receives FDA Fast Track Designation for Resolaris™ to Treat Facioscapulohumeral Muscular Dystrophy (FSHD)

    SAN DIEGO, Oct. 24, 2016 /PRNewswire/ -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced that its product candidate Resolaris™ was granted Fast Track designation by the US Food and Drug Administration (FDA) for the treatment of facioscapulohumeral muscular dystrophy (FSHD), making it the first known therapeutic candidate for the treatment of FSHD to receive the designation.  Resolaris, a designated Orphan Drug in FSHD, is currently being studied in a Phase 1b/2 clinical program. "This Fast Track designation, which is granted to drug candidates addressing serious conditions and that demonstrate the potential to address unmet medical needs, represents another step forward for our rare muscle disease franchise," said John Mendlein, PhD, CEO of aTyr Pharma.

  • Investopedia15 days ago

    BMO Sets $8 Target for Atyr Pharma (LIFE)

    Atyr Pharma has seen its stock crater by 70% since January. But one analyst thinks LIFE shares have a potential upside of 175.8%.